Which peptides are in this family?
-
Elamipretide
Synthetic four-amino-acid peptide studied in rare mitochondrial diseases. US accelerated approval for Barth syndrome; not authorised in the UK. A large phase 3 trial failed.
PreliminaryNot licensed in the UK -
EpithalonEpitalon
Synthetic four-amino-acid peptide studied in ageing research. Not licensed in the UK; evidence is mostly laboratory and animal work from one group.
LimitedNot licensed in the UK -
KPVLys-Pro-Val
Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.
PreliminaryNot licensed in the UK -
MOTS-cMitochondrial open reading…
16-amino-acid peptide encoded in mitochondrial DNA, studied in mice and cells. Not licensed in the UK. No published trial gave MOTS-c to people; human studies measured the body's own levels.
PreliminaryNot licensed in the UK -
Thymosin Alpha-1Thymalfasin
Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.
ModerateNot licensed in the UK
Best recorded finding for each peptide in this family
Each row grades one recorded finding, not the peptide or the medicine.
| Peptide | UK status | Finding | Evidence grade |
|---|---|---|---|
| Elamipretide | Not licensed in the UK | Barth syndrome, 168-week extension | Preliminary |
| Epithalon | Not licensed in the UK | Ex-vivo elderly donor lymphocytes | Limited |
| KPV | Not licensed in the UK | PepT1 uptake, cells and mice | Preliminary |
| MOTS-c | Not licensed in the UK | Discovery paper, mice and cells | Preliminary |
| Thymosin Alpha-1 | Not licensed in the UK | Sepsis 28-day mortality | Moderate |
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.